Rev­o­lu­tion Med­i­cines shoots for $150 mil­lion IPO; No­var­tis vet heads to Boston Phar­ma

→ A week af­ter Black­Di­a­mond Ther­a­peu­tics set the ear­ly bar for 2020 IPOs, Rev­o­lu­tion Med­i­cines has priced its own — and it’s big: $150 mil­lion. The on­col­o­gy biotech launched out of Third Rock Ven­tures back in 2015 but gained steam last year when it raised $100 mil­lion and picked up a RAS pro­gram from the now-de­funct Warp Dri­ve Bio. It al­so has an SHP2 pro­gram part­nered with and heav­i­ly sub­si­dized by Sanofi. The range for their IPO will be $14-$16 and they hope to sell 10 mil­lion shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER